\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ tenderness\\ to\\ palpation\\ of\\ right\\ upper\\ arm\\.\\ active\\ elbow\\ flexion\\ and\\ extension\\ limited\\ by\\ pain\\ in\\ upper\\ arm\\.\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ laboratory\\ data\\:\\ anemia\\,\\ hypercalcemia\\,\\ azotemia\\,\\ spep\\ m\\ spike\\,\\ peripheral\\ blood\\ smear\\ shows\\ rouleux\\ formation\\,\\ bm\\ aspirate\\ with\\ plasmacytosis\\ \\(60\\%\\)\\.\ \(0\)\
\-\ treatment\\ usually\\ consists\\ of\\ chemotherapy\\ with\\ alkylating\\ agents\\ and\\ induces\\ remission\\ in\\ 50\\ to\\ 70\\ percent\\ of\\ patients\\.\\ \\ however\\,\\ median\\ survival\\ is\\ 3\\ years\\.\\ those\\ with\\ multiple\\ lesions\\ rarely\\ survive\\ longer\\ than\\ a\\ year\\.\\ \\ new\\ therapies\\ include\\ peripheral\\ stem\\ cell\\ transplants\\ in\\ combination\\ with\\ the\\ traditional\\ chemotherapy\\ regimen\\.\\ this\\ combined\\ therapy\\ has\\ induced\\ remission\\ in\\ 50\\ percent\\ of\\ patients\\.\\ \\ complications\\ such\\ as\\ recurrent\\ infections\\,\\ pathologic\\ fractures\\,\\ and\\ renal\\ failure\\ are\\ common\\.\ \(0\)\
\-\ lateral\\ radiograph\\ of\\ the\\ humerus\\ shows\\ extensive\\ lytic\\ lesions\\ of\\ the\\ medullary\\ canal\\ with\\ endosteal\\ scalloping\\ \\ consistent\\ with\\ multiple\\ myeloma\\.\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ lateral\\ radiograph\\ of\\ the\\ skull\\ shows\\ small\\ lytic\\ lesions\\ in\\ the\\ frontal\\ region\\ consistent\\ with\\ multiple\\ myeloma\\.\ \(0\)\
\-\ multiple\\ myeloma\ \(25\)\
\-\ multiple\\ myeloma\\,\\ metastatic\\ cancer\\,\\ mgus\ \(0\)\
\-\ 64\\ yo\\ wm\\ with\\ right\\ arm\\/shoulder\\ pain\\ that\\ worsens\\ with\\ movement\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ myeloma\\:\\ 0\\.3460992832899664\ \(0\)\
\-\ multiple\\:\\ 0\\.203765719058102\ \(0\)\
\-\ remission\\:\\ 0\\.20230433455860566\ \(0\)\
\-\ arm\\:\\ 0\\.1995049091115997\ \(0\)\
\-\ percent\\:\\ 0\\.16479518856511507\ \(0\)\
\-\ with\\:\\ 0\\.14683414379631404\ \(0\)\
\-\ shows\\:\\ 0\\.14670316249387358\ \(0\)\
\-\ lesions\\:\\ 0\\.14355316715306538\ \(0\)\
\-\ lytic\\:\\ 0\\.14036639550663843\ \(0\)\
\-\ azotemia\\:\\ 0\\.13324524430274604\ \(0\)\
\-\ rouleux\\:\\ 0\\.13324524430274604\ \(0\)\
\-\ plasmacytosis\\:\\ 0\\.13324524430274604\ \(0\)\
\-\ alkylating\\:\\ 0\\.13324524430274604\ \(0\)\
\-\ mgus\\:\\ 0\\.13324524430274604\ \(0\)\
\-\ peripheral\\:\\ 0\\.11916004964282084\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.11832402629548808\ \(0\)\
\-\ induces\\:\\ 0\\.11719870579102444\ \(0\)\
\-\ 50\\:\\ 0\\.11637581268030996\ \(0\)\
\-\ spike\\:\\ 0\\.11494715185705655\ \(0\)\
\-\ of\\:\\ 0\\.1141361377486921\ \(0\)\
\-\ spep\\:\\ 0\\.11299676712499522\ \(0\)\
\-\ transplants\\:\\ 0\\.11127640586817825\ \(0\)\
\-\ bm\\:\\ 0\\.10973749028389344\ \(0\)\
\-\ survive\\:\\ 0\\.10973749028389344\ \(0\)\
\-\ radiograph\\:\\ 0\\.10853414501603706\ \(0\)\
\-\ worsens\\:\\ 0\\.10707446720214903\ \(0\)\
\-\ traditional\\:\\ 0\\.10482291326818112\ \(0\)\
\-\ in\\:\\ 0\\.10363533499209497\ \(0\)\
\-\ smear\\:\\ 0\\.1028725285361198\ \(0\)\
\-\ aspirate\\:\\ 0\\.10198703386364044\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.09757186237694031\ \(0\)\
\-\ therapies\\:\\ 0\\.09757186237694031\ \(0\)\
\-\ endosteal\\:\\ 0\\.09418612423672751\ \(0\)\
\-\ patients\\:\\ 0\\.09374300580754098\ \(0\)\
\-\ wm\\:\\ 0\\.09321201742913846\ \(0\)\
\-\ regimen\\:\\ 0\\.09229883329091638\ \(0\)\
\-\ scalloping\\:\\ 0\\.09062773410037395\ \(0\)\
\-\ consistent\\:\\ 0\\.0903549656843981\ \(0\)\
\-\ upper\\:\\ 0\\.08904878299226685\ \(0\)\
\-\ stem\\:\\ 0\\.08809689462488716\ \(0\)\
\-\ agents\\:\\ 0\\.08713350009412954\ \(0\)\
\-\ median\\:\\ 0\\.08622973626504082\ \(0\)\
\-\ longer\\:\\ 0\\.08483761778378539\ \(0\)\
\-\ the\\:\\ 0\\.08312581309355896\ \(0\)\
\-\ consists\\:\\ 0\\.0828540748336133\ \(0\)\
\-\ lateral\\:\\ 0\\.08269879514195554\ \(0\)\
\-\ combined\\:\\ 0\\.08262405135836896\ \(0\)\
\-\ induced\\:\\ 0\\.08262405135836896\ \(0\)\
\-\ data\\:\\ 0\\.0817385566858896\ \(0\)\
\-\ survival\\:\\ 0\\.0813151592493285\ \(0\)\
\-\ elbow\\:\\ 0\\.07865213616758408\ \(0\)\
\-\ humerus\\:\\ 0\\.07865213616758408\ \(0\)\
\-\ 64\\:\\ 0\\.07830844527973647\ \(0\)\
\-\ combination\\:\\ 0\\.07732338519918946\ \(0\)\
\-\ movement\\:\\ 0\\.07670175143552278\ \(0\)\
\-\ anemia\\:\\ 0\\.07655039061153612\ \(0\)\
\-\ rarely\\:\\ 0\\.07432036385730133\ \(0\)\
\-\ medullary\\:\\ 0\\.07368796253781715\ \(0\)\
\-\ infections\\:\\ 0\\.0735647028290755\ \(0\)\
\-\ those\\:\\ 0\\.07129562497122398\ \(0\)\
\-\ flexion\\:\\ 0\\.07077945151267659\ \(0\)\
\-\ pe\\:\\ 0\\.06887987096680939\ \(0\)\
\-\ 70\\:\\ 0\\.06879107927206378\ \(0\)\
\-\ pathologic\\:\\ 0\\.0682693742138271\ \(0\)\
\-\ skull\\:\\ 0\\.06760154640740801\ \(0\)\
\-\ recurrent\\:\\ 0\\.06680753632189171\ \(0\)\
\-\ limited\\:\\ 0\\.06650163637053325\ \(0\)\
\-\ formation\\:\\ 0\\.06605447321955736\ \(0\)\
\-\ extensive\\:\\ 0\\.06419612526842591\ \(0\)\
\-\ canal\\:\\ 0\\.06413163867888627\ \(0\)\
\-\ complications\\:\\ 0\\.06381340847010127\ \(0\)\
\-\ failure\\:\\ 0\\.0632575033242613\ \(0\)\
\-\ 60\\:\\ 0\\.06231862990262445\ \(0\)\
\-\ active\\:\\ 0\\.06187089557267129\ \(0\)\
\-\ fractures\\:\\ 0\\.06159787474872861\ \(0\)\
\-\ laboratory\\:\\ 0\\.06050385209981451\ \(0\)\
\-\ pain\\:\\ 0\\.05962921995250023\ \(0\)\
\-\ extension\\:\\ 0\\.05898000220928929\ \(0\)\
\-\ new\\:\\ 0\\.05764142402609553\ \(0\)\
\-\ palpation\\:\\ 0\\.05618941334895925\ \(0\)\
\-\ cancer\\:\\ 0\\.05549635553683219\ \(0\)\
\-\ right\\:\\ 0\\.055247402029551126\ \(0\)\
\-\ frontal\\:\\ 0\\.05362634746693779\ \(0\)\
\-\ such\\:\\ 0\\.05359503729673834\ \(0\)\
\-\ usually\\:\\ 0\\.05245240724619973\ \(0\)\
\-\ tenderness\\:\\ 0\\.05225133559174271\ \(0\)\
\-\ yo\\:\\ 0\\.05205299438371769\ \(0\)\
\-\ renal\\:\\ 0\\.05188510530762969\ \(0\)\
\-\ and\\:\\ 0\\.051650563413669665\ \(0\)\
\-\ years\\:\\ 0\\.05107344156979971\ \(0\)\
\-\ region\\:\\ 0\\.04983766913009697\ \(0\)\
\-\ include\\:\\ 0\\.04957405561398599\ \(0\)\
\-\ however\\:\\ 0\\.04931511559012635\ \(0\)\
\-\ blood\\:\\ 0\\.04838850372204633\ \(0\)\
\-\ therapy\\:\\ 0\\.0478721781925264\ \(0\)\
\-\ cell\\:\\ 0\\.047662315547688336\ \(0\)\
\-\ common\\:\\ 0\\.047251425195212374\ \(0\)\
\-\ than\\:\\ 0\\.04723118099404376\ \(0\)\
\-\ metastatic\\:\\ 0\\.045696312005935255\ \(0\)\
\-\ small\\:\\ 0\\.04297875424177833\ \(0\)\
\-\ to\\:\\ 0\\.041659180396470284\ \(0\)\
\-\ treatment\\:\\ 0\\.039689268105926497\ \(0\)\
\-\ has\\:\\ 0\\.038057698543855135\ \(0\)\
\-\ that\\:\\ 0\\.03615732811134767\ \(0\)\
\-\ by\\:\\ 0\\.035382086244852305\ \(0\)\
\-\ as\\:\\ 0\\.03347220552865447\ \(0\)\
\-\ are\\:\\ 0\\.03161577703596673\ \(0\)\
\-\ this\\:\\ 0\\.02862991416028683\ \(0\)\
\-\ year\\:\\ 0\\.02567728014961766\ \(0\)\
\-\ is\\:\\ 0\\.022817478450229436\ \(0\)\
